Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNK-UT009 Cell Injection in Type 1 Diabetes
NCT07051564Phase 1Recruiting
- Sponsor
- Zibo City Central Hospital
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CNK-UT009 in type 1 diabetes mellitus (T1D), sponsored by Zibo City Central Hospital. Primary endpoints: Adverse events occurring after the reinfusion of CNK-UT009 cell injection at 12 months and Changes in serum C-peptide peak and area under the curve (AUC) at 12 months. Started May 2025; status: recruiting.
02
Drugs
CNK-UT009
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07051564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051564.